gMendel
gMendel is a biotechnology company focused on affordable, accurate, and scalable genetic disorder screening solutions, especially for prenatal and newborn care. Their key products include PHIVEA® and the gMendel®Test, which leverage AI and advanced genomic technologies to improve early diagnosis and intervention for genetic disorders. The company addresses significant global health challenges by reducing false positives in the Global North and providing access to genetic screening in the Global South. gMendel aims to improve infant mortality rates and reduce lifetime healthcare costs, operating in a growing €30 billion genetic disorder screening market expected to double by 2030. They have achieved milestones such as ISO 13485 certification, European Innovation Council Seal of Excellence, and successful pilot validation studies, positioning them as an innovative player in AI-powered healthcare solutions.
gMendel
gMendel is a biotechnology company focused on affordable, accurate, and scalable genetic disorder screening solutions, especially for prenatal and newborn care. Their key products include PHIVEA® and the gMendel®Test, which leverage AI and advanced genomic technologies to improve early diagnosis and intervention for genetic disorders. The company addresses significant global health challenges by reducing false positives in the Global North and providing access to genetic screening in the Global South. gMendel aims to improve infant mortality rates and reduce lifetime healthcare costs, operating in a growing €30 billion genetic disorder screening market expected to double by 2030. They have achieved milestones such as ISO 13485 certification, European Innovation Council Seal of Excellence, and successful pilot validation studies, positioning them as an innovative player in AI-powered healthcare solutions.